The new year has been under way for about a month now, and speculation about the upcoming 12 months already abounds. Not to be left at the starting gate, here’s a look from Chain Drug Review’s headquarters into what just might happen between now and December 31 and what will remain anyone’s guess.
How could an economic downturn in 2023 impact the most vulnerable patients? If we look at lessons from past recessions, we see that increases in unemployment, inflation and financial stress significantly impact access to medicines.
including the two biggest, CVS Health and Walgreens Boots Alliance — will soon find themselves caught in the middle of the nation’s culture wars, having been thrust into the debate over abortion rights by a recent shift in policy at the
The new year has gotten off with a stunning development, at least for those with no inside knowledge of chain drug retailing. Heyward Donigan, Rite Aid’s chief executive, announced she is leaving the company she joined three years ago.
As a former CVS executive, I took great pleasure in reading about Katie Pouliot, pharmacy manager of CVS Store 212 in Cranston, R.I. Pouliot received the 2022 Paragon Award from CVS Health.
A key takeaway for our federal and provincial governments in Canada throughout the pandemic was that no matter how daunting, community pharmacy rose to the challenge and delivered.
As we look toward 2023 and a sense of normalcy that has eluded us for the past few years, there are several big things on the horizon to keep an eye on in pharmacy, medication use and high-quality, value-based care.
Specialty pharmacy continues to be dynamic, demanding and disruptive, undergoing rapid and dramatic change.
Last year I reported that the COVID-19 pandemic drove tremendous growth in demand for over-the-counter medicines for pain and fever, dietary supplements for immune support and wellness, and consumer medical devices for self-diagnosis and protection.
As the COVID-19 pandemic enters its third year, the public health emergency (PHE) declaration that has underpinned the country’s COVID-19 response efforts by providing the federal government with emergency powers, regulatory flexibilities and additional resources is currently set to expire in early
It is easy for those who are not health care professionals to overlook the tremendous potential for innovation in our field today. Similarly, anyone who is not a health policy wonk might not see the important ways policy is evolving to improve the delivery of care for millions of patients.
The pharmacy profession and patient care services delivered by the pharmacy team have evolved significantly over the past few years, bringing new opportunities and challenges.
New, exciting trends are emerging in community pharmacy practice, but what’s past is still prologue. Sal D’Angelo, a past president of the National Community Pharmacists Association/National Association of Retail Druggists, was the first person I heard say, “Get into politics or get out of pharmacy.
As we welcome 2023 and the beginning of the 118th Congress, HDA pharmaceutical distributor members’ role as a convener within the health care ecosystem will be more important than ever.
An article by McKinsey & Co. describes the current era with the words: “Return, Reimagine, Reinvent.” I cannot think of better positioning for our industry and for NACDS specifically in the association’s 90th Anniversary year. Our industry can look at the word “Return” from two angles.
